KYV-101 designed as a CD19 CAR T-Cell therapy.
Kyverna Therapeutics revealed in a company press release that the FDA has approved KYV-101 as an investigational new drug (IND) for the treatment of scleroderma, making it the third IND approval for the medication. Reportedly, this will result in multicenter study of KYV-101, an autologous fully human anti-CD19 chimeric antigen receptor (CAR) T cell therapy for the treatment of diffuse cutaneous systemic sclerosis (scleroderma).
“We are immensely proud of being able to bring KYV-101 to patients suffering from scleroderma,” said Peter Maag, PhD, CEO, Kyverna Therapeutics. “We are keen to initiate our KYSA-5 trial in this new patient population and generate data to support our KYV-101 design goals. With the deep B cell depletion from KYV-101 treatment, patients with scleroderma may have a full reset of their immune system to stop the vicious cycle of their overactive immune system.”
Reference: Kyverna Therapeutics Announces FDA Clearance of IND for KYV-101, a Novel Fully Human CD19 CAR T-Cell Therapy to Treat Scleroderma. PR Newswire. October 11, 2023. Accessed October 11, 2023. https://www.prnewswire.com/news-releases/kyverna-therapeutics-announces-fda-clearance-of-ind-for-kyv-101-a-novel-fully-human-cd19-car-t-cell-therapy-to-treat-scleroderma-301953561.html
Source link
#FDA #Approves #IND #Kyverna #Therapeutics #Scleroderma #Treatment
